varsity.co.uk Traffic Analytics & Website Stats
varsity.co.uk is a domain having .co.uk extension. varsity.co.uk is a science and education/universities and colleges website. varsity.co.uk gets 390,859 traffic per month, the site is estimated to be worth $183,781.00. Over the last three months, varsity.co.uk's global ranking has decreased from 120,019 to 172,700. varsity.co.uk's traffic has decreased by 0.54% compared to last month, which is already a sign. Which countries sent the most traffic to varsity.co.uk lately? Last month UK was the top country sending traffic to varsity.co.uk. varsity.co.uk's audience is 52.10% male and 47.90% female. The largest age group of visitors are 25 - 34 year olds.
- Traffic Report
-
Monthly Unique Visitors:
255,251
-
Monthly Pageviews:
390,859
- Estimated Valuation
-
Income Per Day:
$ 383
-
Estimated Worth:
$ 183,781
- Geography & Country Targeting
-
Countries Total Count:
46
-
Hot Country & Region:
UK
- Search keywords & Backlinks
-
Keywords Total Count:
2,961
-
Backlinks Sites:
8
- Global Ranks
-
Global Rank:
172,700
-
Country Rank:
200
- Global Rank Change
-
Global Rank Change:
-17,628
-
Country Rank Change:
-8,052
- Web Information
- HTTP Information
- Whois Information
Web Server Information
-
Hosted IP Address:
131.111.182.211
-
Hosted Country:
GB
-
Location Latitude:
52.211799621582
-
Location Longitude:
0.10059999674559
Page Title of varsity.co.uk
Meta Description of varsity.co.uk
Meta Tags of varsity.co.uk
Website Inpage Analysis
-
H1 Headings:
0
-
H2 Headings:
0
-
H3 Headings:
0
-
H4 Headings:
0
-
H5 Headings:
0
-
H6 Headings:
0
-
Total IFRAMEs:
0
-
Total Images:
0
-
Total Forms:
0
-
Total Scripts:
0
-
Google Adsense:
No Data
-
Google Analytics:
No Data
HTTP Header Analysis
Server: nginx
Date: Mon, 24 Oct 2022 09:08:07 GMT
Content-Type: text/html
Content-Length: 138
Connection: keep-alive
Location: https://www.varsity.co.uk/
Full WHOIS Lookup
Domain name:
varsity.co.uk
Data validation:
Nominet was able to match the registrant's name and address against a 3rd party data source on 12-May-2016
Registrar:
Michael Derringer t/a Happyserver Limited [Tag = DERRINGER]
URL: http://www.happyserver.net
Relevant dates:
Registered on: before Aug-1996
Expiry date: 10-Mar-2025
Last updated: 07-Jun-2016
Registration status:
Registered until expiry date.
Name servers:
ns-a.happyserver.co.uk
ns-b.happyserver.co.uk
ns-c.happyserver.uk
ns0.portfast.net
ns1.portfast.net
ns2.portfast.net.uk 213.5.89.46 2a03:9800:0:52::2
WHOIS lookup made at 10:13:00 24-Oct-2022
--
This WHOIS information is provided for free by Nominet UK the central registry
for .uk domain names. This information and the .uk WHOIS are:
Copyright Nominet UK 1996 - 2022.
You may not access the .uk WHOIS or use any data from it except as permitted
by the terms of use available in full at https://www.nominet.uk/whoisterms,
which includes restrictions on: (A) use of the data for advertising, or its
repackaging, recompilation, redistribution or reuse (B) obscuring, removing
or hiding any or all of this notice and (C) exceeding query rate or volume
limits. The data is provided on an 'as-is' basis and may lag behind the
register. Access may be withdrawn or restricted at any time.
Similarly Ranked Websites
-
Watch the trailer, find screenings & book tickets for Top Gun on the official site. Now Playing Only In Theatres, brought to you by Paramount Pictures. Directed by: Joseph Kosinski. Starring: Tom Cruise, Miles Teller, Jennifer Connelly, Jon Hamm, Glen Powell, Lewis Pullman, Charles Parnell, Bashir Salahuddin, Monica Barbaro, Jay Ellis, Danny Ramirez, Greg Tarzan Davis, with Ed Harris, and Val Kilmer
topgunmovie.com 199,898 -
Nikos Pekiaridis/NurPhoto via Getty Images(NEW YORK) -- Pfizer and BioNTech have launched a clinical trial on a vaccine targeting both COVID-19 and influenza, the companies announced Thursday. The phase 1 trial is being done in the United States with 180 participants between the ages of 18 and 64, with the first participant dosed this week, the companies said. The follow-up period for each participant will be six months. "By combining both indications in one vaccine approach, we aim to provide individuals with an efficient way to receive immunization against two severe respiratory diseases with evolving viruses that require vaccine adaptation," Dr. Ugur Sahin, CEO and co-founder of BioNTech, said in a statement. The combination vaccine is based on the currently available bivalent COVID-19 booster and a quadrivalent mRNA flu vaccine, which is designed to protect against four different flu viruses. The phase 1 trial will test for safety, immune response and optimal dose level of the combination vaccine, before moving on to larger trials. The data will also provide insight into the potential of mRNA vaccines to address more than one pathogen, Sahin said. Annaliesa Anderson, senior vice president and chief scientific officer of vaccine research and development for Pfizer, called this an "exciting step in our ongoing journey with BioNTech as we collectively look to transform the prevention of infectious diseases around the world." "Even with existing seasonal influenza vaccines, the burden of this virus is severe across the world causing thousands of deaths and hospitalizations every year," she said in a statement. Studies indicate COVID-19 vaccine efficacy fades over time, though it's not clear if every American will need an annual COVID-19 booster. As scientists continue to assess the need, several companies are at work on creating a single injection each fall that protects against both seasonal flu and COVID-19. In addition to Pfizer, pharmaceutical companies Moderna and Novavax have announced plans to work on a combo shot. Moderna said it anticipates starting clinical trials on a single-dose vaccine that combines a booster against COVID-19 and a booster against flu by the end of the year, with hopes of the vaccine being available for the 2023 season. "We believe this is a very large opportunity that is ahead of us, if we could bring to market a high efficacy pan-respiratory annual booster," Moderna COE Stéphane Bancel said during the Sept. 9 investor meeting. Last year, Novavax enrolled people in a Phase 1/2 study to evaluate the safety, tolerability and immune response of a combination vaccine using the company's seasonal influenza and COVID-19 vaccines. A phase 2 confirmation trial is expected to begin later this year, the company said in October. Copyright © 2022, ABC Audio. All rights reserved.
mycentraloregon.com 1,173,413 -
buy.palacecinemas.com.au
buy.palacecinemas.com.au 83,562 -
The Varsity Hotel Cambridge Official Site. Experience a luxury riverside spa hotel in the centre of Cambridge. Book direct for best rates.
thevarsityhotel.co.uk 1,363,114 -
ticketsforthe.show
ticketsforthe.show 878,380 -
sr2.cinema-city.pl
sr2.cinema-city.pl 17,048 -
Sports collecting news and features. Original content centered on modern and vintage sports cards and collectibles. Links to items for sale.
sportscollectorsdaily.com 298,959 -
Encontre todos os artigos mais recentes e veja programas de TV, reportagens e podcasts relacionados com Portugal em portalcascais.pt
portalcascais.pt 3,298,192 -
vupulse makes digital marketing and advertising more effective for marketers, more profitable for brands, and better experiences for consumers.
vupulse.com 414,897 -
omniwebticketing5.com
omniwebticketing5.com 293,575